We propose a model whereby in the context of normal cells, or in cancers that do not have abundant activated β-catenin, an up-regulation of TCF-4 would enhance repression of TCF/β-catenin responsive genes in conjunction with the other 1,25(OH)2D3-mediated β-catenin crosstalk previously mentioned. The gene discussed is TCF4; the disease is cancer.